207 related articles for article (PubMed ID: 22948225)
1. Adherence to uric acid treatment guidelines in a rheumatology clinic.
Conway R; Coughlan RJ; Carey JJ
Clin Rheumatol; 2012 Dec; 31(12):1707-11. PubMed ID: 22948225
[TBL] [Abstract][Full Text] [Related]
2. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
Corbett EJM; Pentony P; McGill NW
Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
[TBL] [Abstract][Full Text] [Related]
3. Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.
Shen M; Zhang J; Qian K; Li C; Xu W; Gu B; Wang X; Ren Q; Yang L; Yuan H; Su D; Chen X
Clin Rheumatol; 2018 Nov; 37(11):3107-3113. PubMed ID: 30196323
[TBL] [Abstract][Full Text] [Related]
4. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
[TBL] [Abstract][Full Text] [Related]
5. Opportunities for improving medication use and monitoring in gout.
Singh JA; Hodges JS; Asch SM
Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
[TBL] [Abstract][Full Text] [Related]
6. Febuxostat for treating chronic gout.
Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
[TBL] [Abstract][Full Text] [Related]
7. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
8. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
Quilisadio JEC; Salido EO; Penserga EG
Mod Rheumatol; 2021 May; 31(3):755-761. PubMed ID: 32701037
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
Wu J; Zhang YP; Qu Y; Jie LG; Deng JX; Yu QH
Int J Rheum Dis; 2019 Aug; 22(8):1445-1451. PubMed ID: 31317680
[TBL] [Abstract][Full Text] [Related]
10. Febuxostat efficacy in allopurinol-resistant tophaceous gout.
Uh M; Reid G
J Clin Rheumatol; 2011 Jun; 17(4):204-6. PubMed ID: 21617552
[TBL] [Abstract][Full Text] [Related]
11. [A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient].
Sun Y; Li L; Zhou TY; Lu W
Yao Xue Xue Bao; 2014 Dec; 49(12):1674-83. PubMed ID: 25920196
[TBL] [Abstract][Full Text] [Related]
12. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
13. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
14. Febuxostat--treatment for hyperuricemia and gout?
Moreland LW
N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
[No Abstract] [Full Text] [Related]
15. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
[TBL] [Abstract][Full Text] [Related]
16. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.
Borghi C; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):983-92. PubMed ID: 27010159
[TBL] [Abstract][Full Text] [Related]
17. Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.
Hilmi BA; Asmahan MI; Rosman A
Med J Malaysia; 2012 Feb; 67(1):125-6. PubMed ID: 22582566
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the therapeutic effects of febuxostat combined with a low-purine diet and allopurinol combined with a low-purine diet on the improvement of gout patients.
Chen X; Ye T; Dai Y; Li P; Zhao X; Yu Y; Wang X; Jiao X; Shen N
Int J Rheum Dis; 2024 May; 27(5):e15165. PubMed ID: 38769820
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
Faruque LI; Ehteshami-Afshar A; Wiebe N; Tjosvold L; Homik J; Tonelli M
Semin Arthritis Rheum; 2013 Dec; 43(3):367-75. PubMed ID: 24326033
[TBL] [Abstract][Full Text] [Related]
20. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
